Moreover , subgroup analyses suggested that the effects of glycemic control were significantly influenced by the sex of the subjects and the type and the method of intake of ITF .
Conclusions Our analyses confirmed that these four main glycemic indicators were significantly reduced by ITF supplementation , particularly in the prediabetes and T2DM population .
Evidence supports that reasonable administration of ITF supplementation may have potential clinical value as an adjuvant therapy for prediabetes and T2DM management .
Background Currently , many clinical trials have shown that inulin-type fructans ( ITF ) supplementation is associated with glycemic control ; nevertheless , the results are inconclusive .
The aim of this meta- analysis of r and omized controlled trials was to assess the effects of ITF supplementation on glycemic control .
Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults.
BACKGROUND Rodent studies show that oligofructose promotes weight loss , stimulates satiety hormone secretion , reduces energy intake , and improves lipid profiles . OBJECTIVE Our objective was to examine the effects of oligofructose supplementation on body weight and satiety hormone concentrations in overweight and obese adults . DESIGN This study was a r and omized , double-blind , placebo-controlled trial . Forty-eight otherwise healthy adults with a body mass index ( in kg/m2 ) > 25 were r and omly assigned to receive 21 g oligofructose/d or a placebo ( maltodextrin ) for 12 wk . Body composition ( by dual-energy X-ray absorptiometry ) ; meal tolerance tests , including satiety hormone response ; food intake ; and subjective appetite ratings were determined . RESULTS There was a reduction in body weight of 1.03 + /- 0.43 kg with oligofructose supplementation , whereas the control group experienced an increase in body weight of 0.45 + /- 0.31 kg over 12 wk ( P = 0.01 ) . A lower area under the curve ( AUC ) for ghrelin ( P = 0.004 ) and a higher AUC for peptide YY ( PYY ) with oligofructose ( P = 0.03 ) coincided with a reduction in self-reported caloric intake ( P < or = 0.05 ) . Glucose decreased in the oligofructose group and increased in the control group between initial and final tests ( P < or = 0.05 ) . Insulin concentrations mirrored this pattern ( P < or = 0.05 ) . Oligofructose supplementation did not affect plasma active glucagon-like peptide 1 secretion . According to a visual analog scale design ed to assess side effects , oligofructose was well tolerated . CONCLUSIONS Independent of other lifestyle changes , oligofructose supplementation has the potential to promote weight loss and improve glucose regulation in overweight adults . Suppressed ghrelin and enhanced PYY may contribute in part to the reduction in energy intake . The trial was registered at clinical trials.gov as NCT00522353
Moreover , subgroup analyses suggested that the effects of glycemic control were significantly influenced by the sex of the subjects and the type and the method of intake of ITF .
Conclusions Our analyses confirmed that these four main glycemic indicators were significantly reduced by ITF supplementation , particularly in the prediabetes and T2DM population .
Evidence supports that reasonable administration of ITF supplementation may have potential clinical value as an adjuvant therapy for prediabetes and T2DM management .
Background Currently , many clinical trials have shown that inulin-type fructans ( ITF ) supplementation is associated with glycemic control ; nevertheless , the results are inconclusive .
The aim of this meta- analysis of r and omized controlled trials was to assess the effects of ITF supplementation on glycemic control .